Shelter Pharma Ltd Secures Renewal of Manufacturing Licence for Ayurvedic Products
Shelter Pharma Ltd has received a critical Renewal Manufacturing Licence (Form 25D) for its Ayurvedic operations. The renewal, granted by the Food & Drugs Control Administration (Ayurved), Government of Gujarat, allows the company to continue the manufacture and sale of Ayurvedic, Siddha, and Unani Drugs.The manufacturing facility responsible for the products is located at Near S.T Bus Stand, Himatnagar - 383001 Gujarat.
The newly renewed licence is valid until September 2030. The company stated that this renewal ensures the uninterrupted continuation of its manufacturing operations.
Management expressed that the secured licence reflects the company's strong regulatory compliance framework, providing a solid foundation for sustained growth in the Ayurvedic healthcare sector.
Key details regarding the renewed approval are as follows:
| Particulars | Details |
|---|---|
| Licensing Authority | Food & Drugs Control Administration (Ayurved), Government of Gujarat |
| License Details | Renewal of Manufacturing Licence (Form 25D) for manufacture and sale of Ayurvedic, Siddha and Unani Drugs |
| Operational Impact | Enables the Company to continue its manufacturing operations and supports its business growth in the Ayurvedic healthcare sector. |
| Validity Period | Up to September 2030 |
| Status | The licence is valid up to September 2030, subject to compliance with applicable regulatory requirements. |
Stock Price Movement
As of 14:54, Shelter Pharma Ltd is ticking down slightly, trading at ₹31.98, marking a 0.03% dip for the day. The shares have been completely locked at this single price point throughout the entire trading session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.